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ABSTRACT
Erythromycin is considered to be one of the safest antimicrobials exhibiting good activity against Gram-positive aerobes and some 
Gram-negative aerobes but rare cases of hypersensitivity reactions to erythromycin alone or with its base (esteolate or ethylsuccinate) 
can occur. Here, we report the case of severe hypersensitivity reaction in a female patient with upper respiratory tract infection 
and underwent treatment with erythromycin ethylsuccinate (400mg TDS). Twenty-four hours after the initiation of therapy with 
erythromycin ethylsuccinate, the patient developed severe rash starting from the nape of the neck spreading throughout the body with 
generalized pruritus and mild icterus. Marked improvement was noticed within 2 days after cessation of erythromycin ethylsuccinate. 
Physicians must be aware of the adverse effects of erythromycin ethylsuccinate before prescribing the drug.
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Erythromycin, the first macrolide introduced in 1952 is considered to be one of the safest antimicrobials exhibiting good activity against Gram-positive aerobes 
and some Gram-negative aerobes.  Rare cases of hypersensitivity 
reactions (0.4% to 3%) to erythromycin alone or with its base 
(esteolate or ethylsuccinate) have been reported in the literature 
[1]. Erythromycin ethylsuccinate is an ester of erythromycin and 
suitable for oral administration. The patient exhibiting 
hypersensitivity reaction to one member of macrolides is likely 
to have cross-sensitivity to the other members of the same class 
[2,3]. The adverse effects of macrolides may manifest in the form 
of immediate or delayed type of hypersensitivity reactions e.g. 
anaphylaxis, angioedema, urticaria, maculopapular rash, fixed 
drug eruptions, contact dermatitis, toxic epidermal necrolysis, 
etc [4,5,6]. This aim of this case report is to sensitize and warn 
prescribers and consumers to be aware of serious adverse effects 
associated with erythromycin ethylsuccinate.
CASE REPORT
A 29-years-old female patient reported to the department 
with erythematous maculopapular rash on the nape of her 
neck for 2 days. She had given history of upper respiratory 
tract infection (sore throat) with high-grade fever >101°F and 
chills for the last two days, for which, she self-medicated with 
erythromycin ethylsuccinate (400mg twice a day) (Fig. 1) along 
with paracetamol (500mg thrice a day). Twenty-four hours after 
the start of erythromycin ethylsuccinate, the patient developed 
severe erythematous maculopapular rash on the nape of her 
neck spreading throughout the body, with extensive generalized 
pruritus (Fig. 2 and 3). The patient started feeling dyspnoeic 
within 3 hours of the start of symptoms. The patient rushed to the 
casualty of a tertiary care teaching hospital in South Delhi. There 
was no history/evidence suggestive of allergy to any drug. 
On clinical examination, the patient was highly anxious and 
dyspnoeic. The vital parameters were as follows: blood pressure- 
81/50 mm of Hg, pulse rate-68/min and respiratory rate of >26). 
Maculopapular rashes were seen throughout the body with 
generalized pruritis and redness. The patient developed some 
puffiness of the face and mild icterus in the eyes. 
The patient was immediately put on oxygen through an 
oxygen mask and intramuscular injection of 0.5 ml of adrenaline 
(1:1000) was given followed by slow intravenous injection of 
chlorpheniramine (20mg), over 1 minute. Slow intravenous 
Figure 1: Erythromycin ethyl-succinate.
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injection of hydrocortisone (200mg) was added after 10 minutes. 
An extensive evaluation was done to determine the cause of an 
allergic response. Blood sample of the patient was collected for 
routine blood tests including liver function tests. Liver function 
tests were found to be slightly deranged (Alanine aminotransferase 
(ALT) was 29 IU/L, aspartate aminotransferase (AST) was 48 
IU/L and alkaline phosphatase (ALP) was 142 U/L), with total 
bilirubin levels 1.9 mg/Dl, but could not be compared since base 
levels were not available. 
Improvement started within 90 min of initiation of therapy. 
Marked improvement was noticed within 2 days after cessation 
of erythromycin ethylsuccinate. No rechallenge was given to the 
patient with erythromycin ethylsuccinate. Anti-streptolysin O 
titre was also done after 3 weeks to confirm likely streptococcal 
infection, which came out to be negative (<200 IU). Naranjo 
causality assessment scale [7] revealed the total score as 6, which 
falls under “Probable”, means that there is a probability that 
the above event is related to hypersensitivity to erythromycin 
ethylsuccinate. The patient was then labeled with a final diagnosis 
of “Erythromycin ethylsuccinate induced hypersensitivity 
reaction.” No untoward incident was reported during follow-up 
over 3 weeks.
DISCUSSION
Adverse Drug Reactions (ADRs) are the leading cause of hospital 
admissions to the extent of 5-10% cases. Therefore, it is essential 
to recognize ADR and to establish the causal relationship between 
the drug and the adverse event [8]. Erythromycin ethylsuccinate 
is widely prescribed macrolide antimicrobial for upper and lower 
respiratory tract infections. ADRs are although rare but have been 
seen in patients with certain underlying associated risk factors 
such as middle-aged female, elderly, positive history of cardiac 
disease especially arrhythmias and patient with compromised 
renal and hepatic functions. As suggested from a case report 
published in the literature, macrolide antibiotics can interact to 
varying degrees with many commonly prescribed drugs due to 
inhibition of the CYP3A4 metabolic pathway [9].
The most commonly prescribed macrolide being erythromycin 
(esteolate or ethylsuccinate) tends to inhibit CYP3A4, thus liable 
to cause various drug interactions. The common interactions 
of erythromycin ethylsuccinate reported in the literature are 
due to concomitant use of statins (risk of rhabdomyolysis and 
acute renal failure), triazolam, pimozide, warfarin, cyclosporine, 
theophylline, carbamazepine (increased plasma levels due to 
inhibition of drug metabolism), cisapride, quinidine and second-
generation antihistaminics e.g. terfenadine, astemizole, cetirizine, 
levocetirizine (prolongation of QT interval in ECG, manifesting 
as tachycardia and cardiac arrhythmias) [10,11].
Patients receiving concomitant erythromycin ethylsuccinate 
and microsomal enzyme inhibitor drug have 5 times more risk 
of sudden deaths as compared to erythromycin ethylsuccinate 
alone [12,13]. Hence, it is advised not to prescribe erythromycin 
ethylsuccinate concomitantly with microsomal enzyme inhibitor 
drugs as mentioned above. Erythromycin ethylsuccinate alone 
can be prescribed if indicated in such cases with extreme caution 
by suggesting baseline ECG, electrolyte levels, liver, and renal 
function tests and also monitoring of the levels after intake of 
erythromycin. In patients with a history suggestive of skin rash 
following any macrolide dose, the offending drug should not be 
prescribed. Erythromycin ethylsuccinate in such cases should be 
replaced by another suitable antibiotic group [13].
In the present case report, the symptoms of the patient raise the 
possibility of likely immune-mediated hypersensitivity. Since the 
patient refused to take rechallenge with erythromycin in any form 
(esteolate or ethylsuccinate), it is difficult to comment whether the 
symptoms appeared due to hypersensitivity to erythromycin or its 
base ethylsuccinate. Limited data is available in the literature to 
support this fact.
CONCLUSION
Erythromycin base (ethylsuccinate) must be incorporated into the 
list of drugs causing rash and liver function disturbances. Factors 
like self-medication and availability of antibiotics as over the 
counter drugs as in the present case report needs to be curbed in 
society at the earliest to prevent serious adverse effects including 
development of resistant strains in the community. Consumers 
and prescribers must be aware of likely ADRs encountered with 
the use of erythromycin or its base ethylsuccinate and to exercise 
caution before use or prescribing. There is a need to create 
awareness for right reporting of ADRs by drug manufacturers, 
prescribers and voluntary reporting by consumers so as to 
withdraw offending drug/base from the market by regulatory 
Figure 2: Maculopapular rash on the body. Figure 3: Maculopapular rashes on the (a) arms and (b) ear of the patient.
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authorities if adequate data gets generated at the global platform 
with significant adverse evidence. 
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